MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Losartan

CAS No. : 114798-26-4

MCE 國(guó)際站：Losartan

產(chǎn)品活性：Losartan 是血管緊張素II受體拮抗劑，與血管緊張素II競(jìng)爭(zhēng)性結(jié)合AT1受體，IC50為20 nM。

研究領(lǐng)域：GPCR/G Protein

作用靶點(diǎn)：Angiotensin Receptor

In Vitro: Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC₅₀) is 20 nM. Losartan (40?μM) affects I_SC but prevents the effect of ANGII on I_SC. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone.

In Vivo: Losartan (0.6 g/L, p.o.) -treated Fbn1^C1039G/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1^C1039G/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1^C1039G/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Irbesartan hydrochloride  |  Dehydro Olmesartan  |  Losartan Carboxylic Acid  |  A81988  |  Eprosartan  |  Angiotensin III, human, mouse TFA  |  (Sar1,Ile4,8)-Angiotensin II  |  Losartan-d₃ Carboxylic Acid  |  Irbesartan-d₄  |  Saralasin acetate hydrate  |  Allisartan isoproxil  |  TRV-120027  |  Mepixetil  |  Losartan carboxylic acid-d₄ hydrochloride  |  Angiotensin amide  |  Sparsentan  |  YS-49  |  Olmesartan medoxomil (Standard)  |  Azilsartan medoxomil monopotassium  |  Angiotensin II human TFA  |  Angiotensin II (3-8), human TFA  |  [Sar1, Ile8]-Angiotensin II TFA  |  Tranilast sodium  |  SL910102  |  Candesartan Cilexetil  |  L162389  |  L-159282  |  CGP48369  |  Elisartan  |  Pratosartan

熱門產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry